OraSure Technologies, Walgreens and Chronic Liver Disease Foundation to Launch Rapid Hepatitis C Testing Initiative in Support

OraSure Technologies, Walgreens and Chronic Liver Disease Foundation to Launch
Rapid Hepatitis C Testing Initiative in Support of National Hepatitis Testing
Day

Select Walgreens Locations to Offer Rapid HCV Testing With OraQuick(R) HCV
Rapid Test

BETHLEHEM, Pa., May 13, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), Walgreens (NYSE:WAG), and the Chronic Liver Disease Foundation
announced today that they have joined with local health organizations to offer
hepatitis C (HCV) testing with the OraQuick® HCV Rapid Test to individuals who
may be at risk for HCV infection. The testing will be available in select
Walgreens locations across 11 states in observance of National Hepatitis
Testing Day, May 19. The on-site testing, patient education and linkage to
care will be conducted by local health organizations. National Hepatitis
Testing Day was established by the Centers for Disease Control and Prevention
(CDC) as an opportunity to remind healthcare providers and those individuals
at risk that they should be tested for viral hepatitis.

"Today, approximately 4 million Americans are infected with hepatitis C and
the vast majority does not know it," said Dr. Willis C. Maddrey, President of
the Chronic Liver Disease Foundation. "However, new therapies are now
available that can effectively treat and in some cases eliminate the virus
from the body, making testing for HCV – particularly among baby boomers – a
critical step in fighting this epidemic."

"Hepatitis C is a silent epidemic and these testing events can help make a
meaningful impact on prevention, treatment and awareness," said Glen
Pietrandoni, Walgreens senior manager of virology. "By working
collaboratively, we can help educate communities on the risk factors and link
people to appropriate care."

OraQuick® HCV is the first and only FDA-approved and CLIA-waived point of care
test for detection of HCV infection in at-risk individuals. The simple
platform enables healthcare providers to deliver a diagnosis based on
lab-accurate test results in 20 minutes, using venipuncture or fingerstick
blood.

"Using traditional laboratory testing, individuals typically wait days or
weeks before receiving their hepatitis C test results," said Douglas A.
Michels, President and CEO of OraSure Technologies. "The OraQuick® HCV Rapid
Test is ideal for use at the point of care – it's easy, accessible and
provides lab-accurate results in 20 minutes – enabling individuals presumed to
be infected to be referred immediately for follow-up care."

In addition to this initiative with Walgreens and CLDF, OraSure's OraQuick HCV
Rapid Test is being deployed at public testing events in Washington, D.C., Los
Angeles, New York City, Chicago, Pittsburgh, and other cities across the U.S.
in recognition of National Hepatitis Testing Day.

For more information, including Walgreens testing locations and hours, please
visit: http://www.TestHepC.com/Walgreens.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market - making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their
health.

For more information on OraSure Technologies, please visit www.orasure.com.

About Walgreens

As the nation's largest drugstore chain with fiscal 2012 sales of $72 billion,
Walgreens (www.walgreens.com) vision is to become America's first choice for
health and daily living. Each day, Walgreens provides more than 6 million
customers the most convenient, multichannel access to consumer goods and
services and trusted, cost-effective pharmacy, health and wellness services
and advice in communities across America. Walgreens scope of pharmacy services
includes retail, specialty, infusion, medical facility and mail service, along
with respiratory services. These services help improve health outcomes and
lower costs for payers including employers, managed care organizations, health
systems, pharmacy benefit managers and the public sector. The company operates
8,086 drugstores in all 50 states, the District of Columbia and Puerto Rico.
Take Care Health Systems is a Walgreens subsidiary that is the largest and
most comprehensive manager of worksite health and wellness centers and
in-store convenient care clinics, with more than 700 locations throughout the
country.

About the Chronic Liver Disease Foundation

Established in 2001, the Chronic Liver Disease Foundation is a nonprofit
501(c)(3) educational organization dedicated to providing hepatology related
continuing medical education, news and information to healthcare professionals
across the US. The CLDF is led by a Board of Trustees comprised of nationally
renowned liver disease specialists. Furthermore, the CLDF believes that
educational programs should be developed by the specialists who are actively
involved in the research, treatment and management of a disease. As such the
CLDF has developed a network of 75 Centers of Educational Expertise and
multiple Advisory Boards who are actively involved in program creation related
to specific disease topics which include; hemochromatosis, hepatic
encephalopathy, hepatitis B, hepatitis C, hepatocellular carcinoma, HIV
co-infection, liver transplantation and NASH/NAFLD. The CLDF's educational
opportunities are offered in a variety of formats including an interactive web
site, live meetings, teleconferences, print pieces, webcasts and other
electronic mediums. For more information, please visit
www.chronicliverdisease.org.

CONTACT: Media Contact:
         Jennifer Moritz
         Zer0 to 5ive for OraSure Technologies
         917-748-4006
         jmoritz@0to5.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.